Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer

Summary Purpose This phase 1a, first-in-human study assessed the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and antitumor activity of FCN-437c, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Methods The study enrolled female patients with HR + /HER2- advanced breast cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Wang, Xiaojia, Wang, Xian, Hui, Aimin, Wu, Zhuli, Tian, Ling, Xu, Changjiang, Yang, Yuchen, Zhang, Wenjing, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541945/
https://www.ncbi.nlm.nih.gov/pubmed/34109484
http://dx.doi.org/10.1007/s10637-021-01133-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541945/
https://www.ncbi.nlm.nih.gov/pubmed/34109484
http://dx.doi.org/10.1007/s10637-021-01133-2

Ejemplares similares